TCR2 Therapeutics Inc. Common Stock
TCRR
TCRR was delisted on the 31st of May, 2023.
40 hedge funds and large institutions have $152M invested in TCR2 Therapeutics Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 6 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
267% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 6
34% more capital invested
Capital invested by funds: $114M → $152M (+$38.4M)
21% more funds holding
Funds holding: 33 → 40 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$11.3M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$9.98M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.08M |
| 4 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$5.03M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.02M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.25M |
| 3 |
AG
Artal Group
Luxembourg
|
-$283K |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$231K |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$139K |
TCRR Hedge Fund Activity: Q3 2019 in Review
40 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q3 2019, worth a combined $152M — up 34% from $114M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new TCRR positions and 3 closed out — a net gain of 8 holders — while 22 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, adding an estimated $11.3M. The largest seller was Millennium Management, exiting entirely with an estimated $2.02M sold.
- 40 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q3 2019, up from 33 in Q2 2019.
- Funds reported $152M of TCR2 Therapeutics Inc. Common Stock stock for Q3 2019, up 34% quarter-over-quarter.
- 11 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q3 2019 and 3 closed out, a net change of +8 holders.
- The largest TCR2 Therapeutics Inc. Common Stock buyer in Q3 2019 was BlackRock, an estimated $11.3M added.
- The largest TCR2 Therapeutics Inc. Common Stock seller in Q3 2019 was Millennium Management, an estimated $2.02M sold.
Based on aggregated 13F filings for Q3 2019.